Загрузка...
Evolution of Therapies for Chronic Myelogenous Leukemia
The clinical outcome for patients with chronic myeloid leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKI), compounds which inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3243359/ https://ncbi.nlm.nih.gov/pubmed/22157290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e31823dec8d |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|